The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biosimilars Update: FDA Panel Voted to Approve Biosimilars for Etanercept & Adalimumab at July Meeting

Biosimilars Update: FDA Panel Voted to Approve Biosimilars for Etanercept & Adalimumab at July Meeting

July 15, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270During the July meeting of the U.S. Food and Drug Administration’s Arthritis Advisory Committee in Silver Spring, Md., the FDA voted to approve two new biosimilars for use by rheumatologists.

You Might Also Like
  • Tofacitinib Released from FDA REMS Requirement; Plus Biosimilars for Etanercept & Adalimumab Show Promise
  • FDA Panel Supports Novartis Biosimilar of Etanercept
  • FDA Update: Biosiomilar to Adalimumab Receives FDA Approval
Also By This Author
  • Antirheumatic Drugs May Be Linked to Pulmonary Toxicity & More

Etanercept Biosimilar
GP2015, a proposed biosimilar of etanercept (Enbrel), was evaluated at the FDA‘s Arthritis Advisory Committee meeting.1 The panel voted unanimously to recommend approval of GP2015.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The treatment’s proposed indications were:

  1. Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage and improving physical function in patients with moderate to severe active rheumatoid arthritis (RA) in combination with methotrexate (MTX) or as monotherapy;
  2. Reducing signs and symptoms of moderate to severe active polyarticular juvenile idiopathic arthritis in patients aged two years and older;
  3. Reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis in combination with MTX in patients who do not respond adequately to MTX alone;
  4. Reducing signs and symptoms in patients with active ankylosing spondylitis; and
  5. Treating patients 18 years of age or older with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Adalimumab Biosimilar
Additionally, ABP 501, a proposed biosimilar of adalimumab (Humira), was also evaluated at the FDA’s Arthritis Advisory Committee meeting.2 The panel voted unanimously to recommend approval of ABP 501.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

ABP 501 is an anti-tumor necrosis factor (TNF)-α monoclonal antibody with the same amino acid sequence as adalimumab, as well as the same pharmaceutical dosage form and strength as adalimumab in the U.S. and Europe. The proposed indications were:

  1. Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage and improving physical function in adults with moderate to severe active RA as monotherapy or in combination with MTX or other non-biologic, disease-modifying anti-rheumatic drugs (DMARDs);
  2. Reducing the signs and symptoms of moderate to severe active polyarticular juvenile idiopathic arthritis in patients aged four years and older as monotherapy or combined with MTX;
  3. Reducing the signs and symptoms, inhibiting the progression of structural damage and improving physical function in adults with active psoriatic arthritis as a monotherapy or combined with non-biologic DMARDs;
  4. Reducing the signs and symptoms in adults with active ankylosing spondylitis;
  5. Treating adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate—only to be administered to patients who will be closely monitored and have regular follow-up visits with a physician;
  6. Treating Crohn’s disease with specific parameters; and
  7. Treating ulcerative colitis with specific parameters.

The committee reviewed analytical, clinical and pharmacokinetic data from ABP 5101 studies, as well as results from two Phase 3 comparative efficacy and safety studies conducted in both moderate to severe plaque psoriasis and moderate to severe RA patients.3 Primary endpoints in the Phase 3 studies were met, which showed clinical equivalence to adalimumab. Immunogenicity and safety were also comparable to adalimumab. The Biosimilar User Fee Act (BsUFA) target action date of Sept. 25, 2016, was set for this agent.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, Biosimilars, etanercept, FDA, Food and Drug Administration

You Might Also Like:
  • Tofacitinib Released from FDA REMS Requirement; Plus Biosimilars for Etanercept & Adalimumab Show Promise
  • FDA Panel Supports Novartis Biosimilar of Etanercept
  • FDA Update: Biosiomilar to Adalimumab Receives FDA Approval
  • Adalimumab-atto, Biosimilar to Humira, Receives FDA Approval

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.